(e.g., bortezomib, carfilzomib, ixazomib)
Cardio-oncological evaluation* AND BNP or NT-proBNP**
before cancer treatment begins
Cardio-oncological evaluation* AND home blood pressure monitoring, BNP or NT-proBNP**
every 3 months for 1 year, then every 6 months during all proteasome inhibitors therapy
* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.
** TTE and BNP/NT-proBNP must not be performed the day of proteasome inhibitor infusion